# Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT01747798** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 10 (actual)

## Conditions studied

- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** auranofin
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01747798
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-02
- **Primary completion:** 2014-01-10
- **Final completion:** 2015-04-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01747798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01747798, "Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01747798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*